Cyclo Therapeutics, Inc. (CYTH) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
6714 NW 16th Street
Gainesville, FL 32653
United States of America (the)
Phone
386 418 8060
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
8
First IPO Date
May 03, 2000
| Name | Title | Pay | Year Born |
| N. Scott Fine | Chief Executive Officer & Director | 569,919 | 1957 |
| Jeffrey L. Tate | Chief Operating Officer, Chief Quality Officer & Director | 255,138 | 1958 |
| Joshua Fine | Chief Financial Officer & Secretary | 421,174 | 1982 |
| Michael Eric Lisjak | Senior Vice President of Business Development & Chief Regulatory Officer | 430,402 | 1974 |
| Karen Mullen | Interim Chief Medical Officer | 0 | N/A |
| C. E Strattan | Founder & Director | 0 | 1946 |
| Lori McKenna | Global Head of Patient Advocacy | 0 | N/A |
Cyclo Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise focused on developing treatments derived from cyclodextrins for various health conditions. Its flagship therapeutic candidate, Trappsol Cyclo, holds orphan drug status and is presently in Phase III clinical trials targeting Niemann-Pick Type C disease. The company is also investigating Trappsol Cyclo's efficacy in addressing Alzheimer's disease. Beyond its drug development pipeline, the firm engages in the sale of cyclodextrins and related commodities to sectors such as pharmaceuticals and nutrition, primarily for their application in diagnostics and specialized drug formulations. Originally established in 1990 as CTD Holdings, Inc., the company adopted its current name, Cyclo Therapeutics, Inc., in September 2019 and maintains its headquarters in Gainesville, Florida.